CA2361575A1 - L-arginine based formulations for treating diseases and methods of using same - Google Patents

L-arginine based formulations for treating diseases and methods of using same Download PDF

Info

Publication number
CA2361575A1
CA2361575A1 CA002361575A CA2361575A CA2361575A1 CA 2361575 A1 CA2361575 A1 CA 2361575A1 CA 002361575 A CA002361575 A CA 002361575A CA 2361575 A CA2361575 A CA 2361575A CA 2361575 A1 CA2361575 A1 CA 2361575A1
Authority
CA
Canada
Prior art keywords
arginine
nos
agonist
nitric oxide
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002361575A
Other languages
English (en)
French (fr)
Inventor
Wayne H. Kaesemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogenix Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2361575A1 publication Critical patent/CA2361575A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002361575A 1999-02-05 2000-02-04 L-arginine based formulations for treating diseases and methods of using same Abandoned CA2361575A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11890399P 1999-02-05 1999-02-05
US60/118,903 1999-02-05
PCT/US2000/002798 WO2000045809A1 (en) 1999-02-05 2000-02-04 L-arginine based formulations for treating diseases and methods of using same

Publications (1)

Publication Number Publication Date
CA2361575A1 true CA2361575A1 (en) 2000-08-10

Family

ID=22381443

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002361575A Abandoned CA2361575A1 (en) 1999-02-05 2000-02-04 L-arginine based formulations for treating diseases and methods of using same

Country Status (6)

Country Link
EP (1) EP1150669A4 (ja)
JP (1) JP2002536325A (ja)
AU (1) AU3356000A (ja)
CA (1) CA2361575A1 (ja)
MX (1) MXPA01007952A (ja)
WO (1) WO2000045809A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
EP1175210A4 (en) 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc STRENGTHENING THE BIODAVAILABILITY OF DRUGS IN THE BRAIN
JP5065570B2 (ja) * 2002-09-06 2012-11-07 第一三共ヘルスケア株式会社 血管内皮性酸化窒素の合成促進剤
RU2360646C2 (ru) * 2003-08-14 2009-07-10 Блу Медикел Дивайсиз Б.В. Эндолюминальный протез, содержащий лечебное средство
EP1591118A1 (en) * 2004-04-27 2005-11-02 Nutri-Fit GmbH & Co. KG Use of melatonin in preventing postoperative complications
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
CA2147357A1 (en) * 1992-11-04 1994-05-11 Nancy M. Gray Methods and compositions (+) doxazosin for the treatment of hypertension
JPH08511530A (ja) * 1993-06-11 1996-12-03 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 内因性酸化窒素生成又は活性の調節による血管変性疾患の治療
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
DE69533584T2 (de) * 1995-06-01 2005-02-17 N.V. Nutricia Klinische Nährungszusammensetzung
FR2774593B1 (fr) * 1998-02-12 2000-05-05 Philippe Gorny Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds

Also Published As

Publication number Publication date
WO2000045809A1 (en) 2000-08-10
EP1150669A1 (en) 2001-11-07
EP1150669A4 (en) 2005-06-22
JP2002536325A (ja) 2002-10-29
AU3356000A (en) 2000-08-25
MXPA01007952A (es) 2004-03-26

Similar Documents

Publication Publication Date Title
US6465516B1 (en) Method of stimulating nitric oxide synthase
US6425881B1 (en) Therapeutic mixture useful in inhibiting lesion formation after vascular injury
EP0784429B1 (en) Therapeutic combinations of venous dilators and arterial dilators
EP1139753B1 (en) Formulations for treating disease and methods of using same
US7160904B2 (en) Nicotine in therapeutic angiogenesis and vasculogenesis
Settergren et al. L-arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease
Iskesen et al. Trimetazidine reduces oxidative stress in cardiac surgery
WO1996010910A9 (en) Method and formulation of stimulating nitric oxide synthesis
CA2361575A1 (en) L-arginine based formulations for treating diseases and methods of using same
US20030114515A1 (en) Therapeutic mixture of HMG-COA reductase inhibitors
EP1671630A2 (en) L-Arginine based formulations for treating diseases and methods of using the same
CA2388530A1 (en) Therapeutic mixture of hmg-coa reductase inhibitors
Batta Bilirubin as savior of biological system
Oreščanin et al. Effect of L-arginine on the relaxation caused by sodium nitroprusside on isolated rat renal artery
Napoli et al. Nitric oxide in vascular damage and regeneration
KR100356374B1 (ko) 안지오텐신 전환효소 억제제의 부작용으로 발생하는마른기침을 저해하기 위한 철분을 포함하는 기침 저해조성물
MXPA99009243A (en) Method and formulation for treating vascular disease
Piatti et al. L-Arginine in the Prevention and Treatment of Cardiovascular Disease: From Basic to Clinical Research Studies
Hamza et al. Reducing Oxidative Stress and Manipulating Molecular Signaling Events Using Resveratrol as a Therapy for Pathological Cardiac Hypertrophy

Legal Events

Date Code Title Description
FZDE Dead